| 1 |
COVID 19 (Novel Coronavirus 19) Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020 |
Report Link
|
| 2 |
ICOS-Next Generation Immunotherapy - Competitive Landscape and Market Forecast - 2035 |
Report Link
|
| 3 |
LAG-3-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035 |
Report Link
|
| 4 |
TIM-3-Next Generation Immunotherapy - Competitive Landscape and Market Forecast - 2035 |
Report Link
|
| 5 |
Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 |
Report Link
|
| 6 |
Medical Marijuana – Competitive Intelligence Analysis, 2019 |
Report Link
|
| 7 |
Hereditary Transthyretin Amyloidosis (hATTR)- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2030 |
Report Link
|
| 8 |
DUB Inhibitors Competitive Landscape, Market and Pipeline Analysis, 2020 |
Report Link
|
| 9 |
RNA- Competitive Landscape, 2022 |
Report Link
|
| 10 |
Gene Therapy - Competitive Landscape, 2022 |
Report Link
|
| 11 |
COVID-19- Competitive Landscape, 2022 |
Report Link
|
| 12 |
Oncolytic Virus - Competitive Landscape, 2022 |
Report Link
|
| 13 |
Microbiome- Competitive Landscape, 2022 |
Report Link
|
| 14 |
PD-1 and PD-L1 Inhibitors- Competitive Landscape, 2022 |
Report Link
|
| 15 |
Janus kinase (JAK) Inhibitors- Competitive Landscape, 2022 |
Report Link
|
| 16 |
TIGIT Inhibitors - Competitive Landscape, 2022 |
Report Link
|
| 17 |
CAR T - Cell Therapy - Competitive Landscape, 2022 |
Report Link
|
